Immutep ADR

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immutep ADR and other ETFs, options, and stocks.

About IMMP

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). 

CEO
Marc Voigt
CEOMarc Voigt
Employees
—
Employees—
Headquarters
Sydney, New South Wales (NSW)
HeadquartersSydney, New South Wales (NSW)
Founded
1987
Founded1987
Employees
—
Employees—

IMMP Key Statistics

Market cap
23.28M
Market cap23.28M
Price-Earnings ratio
-0.43
Price-Earnings ratio-0.43
Dividend yield
—
Dividend yield—
Average volume
58.17K
Average volume58.17K
High today
$3.41
High today$3.41
Low today
$3.09
Low today$3.09
Open price
$3.41
Open price$3.41
Volume
44.70K
Volume44.70K
52 Week high
$70.60
52 Week high$70.60
52 Week low
$2.66
52 Week low$2.66

IMMP News

TipRanks 2d
Immutep Reports EFTISARC-NEO Disease-Free Survival Data in Soft Tissue Sarcoma

Immutep ( (IMMP) ) has issued an update. Immutep is a clinical-stage biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune diseases....

Benzinga 3d
Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial - Benzinga

...

Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial - Benzinga

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.